Abstract
Statin therapy for aggressive low-density lipoprotein cholesterol (LDL-C) reduction reduces cardiovascular morbidity and mortality. However, even on maximal statin therapy, high-risk patients have substantial residual risk of coronary heart disease (CHD). Certain subgroups, such as individuals with diabetes mellitus, low high-density lipoprotein cholesterol (HDL-C), metabolic syndrome, or other comorbidities, have a particularly high residual risk. Patients at high risk for future CHD events often require multiple aggressive risk-reduction therapies (eg, antiplatelet agents, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blockade, cholesterol and/or diabetes management, and lifestyle interventions) to further lower their overall cardiovascular risk. For cholesterol management, combination therapy may be required to attain optimal levels of LDL-C, HDL-C, and non-HDL-C.
Similar content being viewed by others
References and Recommended Reading
Shepherd J, Cobbe SM, Ford I, et al.:Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group.N Engl J Med 1995,333:1301–1307.
Downs JR, Clearfield M, Weis S, et al.:Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA 1998,279:1615–1622.
Sever PS, Dahlof B, Poulter NR, et al.:Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.Lancet 2003,371:1149–1158.
Scandinavian Simvastatin Survival Study Group:Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet 1994,344:1383–1389.
Sacks FM, Pfeffer MA, Moye LA, et al.:The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators.N Engl J Med 1996,335:1001–1009.
Shepherd J, Blauw GJ, Murphy MB, et al.:Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.Lancet 2002,360:1623–1630.
LIPID Study Group:Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group.N Engl J Med 1998,339:1349–1357.
Nissen SE, Tuzcu EM, Schoenhagen P, et al.:Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.JAMA 2004,291:1071–1080.
Of major importance LaRosa JC, Grundy SM, Waters DD, et al.:Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med 2005,352:1425–1435. The TNT study demonstrated that atorvastatin 80-mg daily is superior to atorvastatin 10-mg daily for reduction of cardiovascular events in patients with stable CHD. Mean LDL-C levels were 77 mg/dL with atorvastatin 80-mg daily and 101 mg/dL with atorvastatin-10 mg daily.
Of importance Nissen SE, Nicholls SJ, Sipahi I, et al.:Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.JAMA 2006,295:1556–1565. The ASTEROID trial demonstrated that intensive therapy with rosuvastatin 40-mg daily results in regression of coronary atherosclerosis, as measured by intravascular ultrasound.
Of major importance Cannon CP, Braunwald E, McCabe CH, et al.:Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med 2004,350:1495–1504. The PROVE-IT study demonstrated that intensive lipid lowering with atorvastatin 80-mg daily is superior to pravastatin 40-mg daily for reduction of cardiovascular events in patients hospitalized for ACS; event rates were 26% versus 22%.
Grundy SM, Cleeman JI, Merz CN, et al.:Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Circulation 2004,110:227–239.
Briel M, Schwartz GG, Thompson PL, et al.Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials.JAMA 2006,295:2046–2056.
Heart Protection Study Collaborative Group:MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet 2002,360:7–22.
Taylor AJ, Sullenberger LE, Lee HJ, et al.:Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.Circulation 2004,110:3512–3517.
Deedwania P, Barter P, Carmena R, et al.:Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.Lancet 2006,368:919–928.
Of importance Ridker PM, Cannon CP, Morrow D, et al.:C-reactive protein levels and outcomes after statin therapy.New Engl J Med 2005,352:20–28. In the PROVE-IT study, patients who achieved both a hsCRP level less than 1 mg/L and an LDL-C level less than 70 mg/dL had the lowest rate of recurrent events (1.9 per 100 person-years). In fact, achievement of these levels was more important than the choice of lipid-lowering therapy. Patients with high hsCRP levels had a high residual risk despite statin therapy; those with hsCRP levels above 2 mg/L had a rate of recurrent events of 4.6 per 100 person-years.
Michos ED, Ardehali R, Blumenthal RS, et al.:Aspirin and clopidogrel resistance.Mayo Clin Proc 2006,81:518–526.
Of importance Nissen SE, Tuzcu EM, Schoenhagen P, et al.:Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.N Engl J Med 2005,352:29–38. In the REVERSAL study, patients with coronary artery disease were randomly assigned to receive atorvastatin 80-mg daily or pravastatin 40-mg daily. Patients with large reductions in hsCRP levels on statin therapy had slower rates of progression of atherosclerosis, even after adjustment for the decrease in lipid levels.
Ridker PM; JUPITER Study Group:Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial Circulation 2003,108:2292–2297.
Assmann G, Benecke H, Neiss A, et al.:Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy: results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians’ Experience and Evaluation).Eur J Cardiovasc Prev Rehabil 2006,13:776–783.
Ansell BJ, Fonarow GC, Maki KC, et al.:Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey.Am Heart J 2006,152:976–981.
Bays HE, Davidson M, Jones MR, Abby SL:Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.Am J Cardiol 2006,97:1198–1205.
Pearson TA, Denke MA, McBride PE, et al.:Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the ezetimibe add-on to statin for effectiveness trial.Mayo Clin Proc 2006,81:1177–1185.
Castro Cabezas M, de Vries JH, Van Oostrom AJ, et al.:Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins.J Am Diet Assoc 2006,106:1564–1569.
Blair SN, Capuzzi DM, Gottlieb SO, et al.:Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.Am J Cardiol 2000,86:46–52.
Gordon DJ, Probstfield JL, Garrison RJ, et al.:High-density lipoprotein and cardiovascular disease: four prospective American studies.Circulation 1995,79:8–15.
King AC, Haskell WL, Young DR, et al.:Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years.Circulation 1995,91:2596–2604.
Maeda K, Noguchi Y, Fukui T:The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis.Prev Med 2003,37:283–290.
Dattilo AM, Krisetherton PM:Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis.Am J Clin Nutr 1992,56:320–328.
Ellison RC, Zhang YQ, Qureshi MM, et al.:Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study.Am Heart J 2004,147:529–535.
Gerasimova E, Perova N, Ozerova I, et al.:The effect of dietary n-3 polyunsaturated fatty acids on HDL cholesterol in Chukot residents vs Muscovites.Lipids 1991,26:261–265.
Alderman JD, Pasternak RC, Sacks FM, et al.:Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high-density lipoprotein cholesterol and the cholesterol to high-density lipoprotein ratio.Am J Cardiol 1989,64:725–729.
Prueksaritanont T, Zhao JJ, Ma B, et al.:Mechanistic studies on metabolic interactions between gemfibrozil and statins.J Pharmacol Exp Ther 2002,301:1042–1051.
McKenney JM, Davidson MH, Shear CL, Revkin JH:Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.J Am Coll Cardiol 2006,48:1782–1790.
Kastelein JJ, van Leuven SI, Burgess L, et al.:Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.N Engl J Med 2007,356:1620–1630.
Nissen SE, Tardif JC, Nicholls SJ, et al.:Effect of torcetrapib on the progression of coronary atherosclerosis.N Engl J Med 2007,356:1304–1316.
Bots ML, Visseren FL, Evans GW, et al.:Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.Lancet 2007,370:153–160.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Campbell, C.Y., Rivera, J.J. & Blumenthal, R.S. Residual risk in statin-treated patients: Future therapeutic options. Curr Cardiol Rep 9, 499–505 (2007). https://doi.org/10.1007/BF02938395
Issue Date:
DOI: https://doi.org/10.1007/BF02938395